Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05947136

PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated With Multiple Myeloma and/or Its Treatments in the Context of a First Hematopoietic Stem Cell Autograft, in Adults Aged 18 to 70.

This is a prospective, multicentre, phase III, randomised, controlled intervention study.

Two groups of patients with equal numbers will be studied and each patient will be allocated to one of the two groups described below by randomisation (ratio 1:1).

Each patient will be allocated to one of the two groups described below by randomisation (ratio 1:1).

- PASCA interventional group

For both the 7 complications of interest (primary objective) and the 13 secondary complications (secondary objective), a specific and proactive referral will be made systematically after each screening assessment, depending on the level of risk, estimated according to decision trees (management guide) and through the dedicated PASCA network of healthcare professionals, in order to initiate early treatment and follow-up if necessary.

- Control group

For the 7 complications of interest (primary objective) as well as for the 13 complications (secondary objective): all the data from each identification check-up will be sent to the onco-haematological transmitted to the referring onco-haematologists, so that they can initiate their own management.

=> For all patients, regardless of group

All patients will receive four screening assessments covering the 7 complications of interest and 13 secondary complications:

* Visit No.1 (T1), 1-2 months after the autologous haematopoietic stem cell transplantation (aHSCT), corresponding to the patient's visit to his or her Multiple Myeloma (MM) monitoring consultation and/or the start of his or her consolidation treatment. * Visit No.2 (T2), 4 months after aHSCT, corresponding to a patient's visit for the end of consolidation treatment; * Visit No.3 (T3), 14 months after the last aHSCT, corresponding to a visit by the patient during his or her maintenance treatment; * Visit No.4 (T4), 24 months after the last aHSCT, corresponding to a visit by the patient for a MM monitoring consultation.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Multiple Myeloma Blood Protein Disorders Cardiovascular Diseases Complication Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders Hemostatic Disorders Immune System Diseases Immunoproliferative Disorders Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Neoplasms, Plasma Cell Paraproteinemias Vascular Diseases

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU La Tronche, Grenoble, France

Loading trial locations.

About this study

After each screening visit, all patients randomised to the intervention group will receive the PASCA intervention:

  • An interpretation of the results of the screening tests concerning
  • the 7 complications of interest assessed at T1, T2, T3 and T4 ;
  • the 13 secondary complications assessed at T1, T3 and T4. This interpretation will be based on decision trees (1 tree/complication) to guide investigators in their decision-making and to standardise orientations;
  • Explanation of results and referrals to the patient using plain language, by a phone call, ;
  • Early, proactive care via a dedicated network of healthcare professionals.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years old and ≤ 70 years old.
  • Patient treated in an investigation center.
  • Symptomatic multiple myeloma eligible for autologous hematopoietic stem cell transplantation (HSCT).
  • In complete response, complete response, very good complete response, or partial before HSCT.
  • First induction-type treatment (Isa-KRD/dara-VRD/dara-VTD/VRD/VTD/dara-VRD), intensification therapy with melphalan, HSCT, consolidation, maintenance including at least one drug immunomodulator.
  • ECOG performance status WHO ≤ 2.
  • No history or coexistence of other primary cancer apart from basal cell cancer cutaneous
  • Able to understand, read and write French.
  • Having signed and dated the informed consent.

Exclusion criteria

  • Unable to be monitored for medical, social, family, geographical or psychological, throughout the duration of the study.
  • Deprived of liberty by court or administrative decision.
  • Not affiliated with a health insurance plan.
  • Not having declared an attending physician.
  • Not domiciled in the Auvergne-Rhône-Alpes region or in the Saône-et-Loire department.
  • Not available and/or not willing to participate in the project for the entire duration of the study.
  • Pregnant women, breastfeeding women, people in emergency situations, people incapable of personally giving their consent including adults under guardianship

Treatment and study plan

Interpretation of the results from the detection visit

Behavioral
  • An interpretation of the results of the detection tests concerning
  • the 7 complications of interest assessed at T1, T2, T3 and T4 ;
  • the 13 secondary complications assessed at T1, T3 and T4. This interpretation will be based on decision trees (1 tree/complication) to guide investigators in their decision-making and to standardise orientations;

Explaining detection results and referrals to the patient

Behavioral

Explanation of results and directions to the patient using plain language;The aims of this call are as follows:

  • Clearly explain the results of the detection visit and the action to be taken for each referral;
  • Evaluate the help to be given to the patient. This help will consist of making bookings with a healthcare professional in the PASCA network;
  • Reassure patients about their results, but also make them aware of the importance of taking action to improve or prevent the onset of complications.

Early medical care through the network

Behavioral

Early, proactive medical care through a network of dedicated healthcare professionals.

Transmission of results from each detection visit to the referring onco-haematologists - Control Group

Behavioral

For both the 7 complications of interest (primary objective) and the 13 secondary complications (secondary objective): all the data from each detection visit will be sent to the referring onco-haematologists, so that they can initiate their own management.

Primary outcomes

  1. change from Baseline high blood pressure

    Time frame: month 2, month 4, month 14 and month 24

    blood pressure ≥ 140/90 mmHg measured in the investigating center and persisting over time

  2. Change from Baseline chronic kidney failure incidence at 24 months

    Time frame: month 2, month 4, month 14 and month 24

    diagnosed on the basis of 2 blood tests carried out within 3 months with the same technique showing either:

    • a decrease in GFR to < 60ml/min/1.73m2, estimated from serum creatinine using the CKD-EPI equation (Chronic Kidney Disease EPIdemiology collaboration, Levey, 2009),
    • positive proteinuria or albuminuria (albuminuria/creatinine ratio),
    • haematuria with a GR > 10/mm3 or 10,000/ml (after eliminating a urological cause),
    • leucocyturia with a WBC >10/mm3 or 10,000/ml (in the absence of infection),
    • a morphological abnormality on renal ultrasound: size asymmetry, bumpy contours, small kidneys or large polycystic kidneys, nephrocalcinosis, cyst.

    The evolutionary character corresponds to one of the following situations:

    • Annual decline in GFR ≥ 5 ml/min/1.73 m²/year: GFR year n - GFR year n+1
    • Presence of albuminuria,
    • Poorly controlled arterial hypertension

  3. Change from Baseline chronic pain incidence at 60 months

    Time frame: month 2, month 4, month 14 and month 24

    pain felt for more than 3 months by the patient with an intensity on the Visual Analogue Scale (VAS) ≥ 3

  4. Change from Baseline sexual disorders incidence at 24 months

    Time frame: month 2, month 4, month 14 and month 24

    at least one perceived problem among the following:

    • disorders of desire,
    • arousal/erection disorders in men,
    • arousal disorders (insufficiency) in women,
    • Orgasm disorders in women

  5. Change from Baseline osteoporosis incidence at 24 months

    Time frame: month 2, month 14 and month 24

    T-score evaluated by osteodensitometry, on the lumbar spine and upper end of the femur

  6. Change from Baseline chronic fatigue incidence at 24 months

    Time frame: month 2, month 4, month 14 and month 24

    Questionnaire "MFI-20" (Multidimensional Fatigue Inventory)

  7. Change from Baseline severe anxiety disorder incidence at 24 months

    Time frame: month 2, month 4, month 14 and month 24

    Questionnaire "HADS-D" (Hospital Anxiety and Depression scale)

Secondary outcomes

  1. Change from Baseline depressive events incidence at 24 months

    Time frame: month 2, month 4, month 14 and month 24

    Defined by at least two main depressive symptoms, associated with at least two symptoms additional information, according to the 2017 HAS recommendation "Characterized depressive episode in adults

    : care in first resort".

  2. Change from Baseline physical deconditioning incidence at 24 months

    Time frame: month 2, month 14 and month 24

    Defined by at least two tests among the 6 min Walk Test (TDM6), Handgrip-test, 60s Sit-to-stand, Flamingo test, with usual values below the norms defined by their authors, according to age and sex

  3. Change from Baseline cognitive problems incidence at 24 months

    Time frame: month 2, month 14 and month 24

    Positive score on at least one of the sub-dimensions of the Functional questionnaire Cancer Therapy Assessment - Cognitive Function (FACT-COG)

  4. Change from Baseline hypogonadism incidence at 24 months

    Time frame: month 2, month 14 and month 24

    Presence of clinical signs as defined by the International Society for Sexual Medicine

    A value below the lower limit on at least one of the following blood assay:

    • level of total testosterone
    • level of bioavailable testosterone

  5. Change from Baseline obesity incidence at 24 months

    Time frame: month 2, month 14 and month 24

    BMI value:

    • [25-30[ kg/m2 with a waist circumference above the norm (≥ 94cm for men or

    ≥ 80cm for women)

    • ≥ 30 kg/m2

  6. Change from Baseline hypothyroidism incidence at 24 months

    Time frame: month 2, month 14 and month 24

    • level of thyroid-stimulating hormone
    • level of total thyroxine

  7. Change from Baseline dyslipidemias incidence at 24 months

    Time frame: month 2, month 14 and month 24

    hypercholesterolemia (LDL) ≥ 1.6 g/L estimated by the Friedewald formula and/or a hypertriglyceridemia ≥ 4 g/L

  8. Change from Baseline Heart failure markers incidence at 24 months

    Time frame: month 2, month 14 and month 24

    NT-proBNP and/or troponin I level above the threshold values.

  9. Change from Baseline Atrial fibrillation incidence at 24 months

    Time frame: month 2, month 14 and month 24

    equivocal electrocardiogram, interpreted by an experienced physician

  10. Change from Baseline of respiratory failure markers incidence at 24 months

    Time frame: month 2, month 14 and month 24

    FVC, FVC, FEV1, FEF25-75, FEF50, FEF25 (established by spirometric test) ≤ 80% of the predicted values (abacus on age, sex, height and origin ethnic)

  11. Change from Baseline return to work issues incidence at 24 months

    Time frame: month 2, month 14 and month 24

    Diagnosed by a social worker

  12. Change from Baseline of Lifestyle risk factors ( tobacco, alcohol, and cannabis) incidence at 24 months

    Time frame: month 2, month 4, month 14 and month 24

    consumption :

    • smoking and/or active cannabis
    • alcohols higher than the latest recommendations

  13. Change from baseline Myelodysplastic syndromes and secondary acute leukemia incidence at 24 months

    Time frame: month 4, month 14 and month 24

    confirmed by the reference diagnosis

Study contacts

Contact information is provided by the study sponsor or research team.

Meyssane DJEBALI, Msc

CONTACT

[email protected]

++33426556743

Romain BUONO, PharmaD, MPH

CONTACT

[email protected]

+33469856358

Sponsors and collaborators

Lead sponsor

Centre Leon Berard

Other

Collaborators

  • National Cancer Institute, France

Registry information

Acronym: PASCA -MM

Important dates

Study start
2024
Primary completion
2028
Study completion
2029
First posted
Jul 17, 2023
Registry last updated
Jun 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.